Send to

Choose Destination
Curr Pathobiol Rep. 2019 Sep;7(3):47-60. doi: 10.1007/s40139-019-00196-4. Epub 2019 Jun 27.

Nanotherapies for Treatment of Cardiovascular Disease: A Case for Antioxidant Targeted Delivery.

Cartaya A1,2,3, Maiocchi S1,2, Bahnson EM1,2,3,4.

Author information

Department of Surgery, Division of Vascular Surgery, University of North Carolina at Chapel Hill, NC 27599.
Center for Nanotechnology in Drug Delivery, University of North Carolina at Chapel Hill, NC 27599.
Department of Pharmacology, University of North Carolina at Chapel Hill, NC 27599.
Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, NC 27599.


Purpose of Review:

Cardiovascular disease (CVD) involves a broad range of clinical manifestations resulting from a dysfunctional vascular system. Overproduction of reactive oxygen and nitrogen species are causally implicated in the severity of vascular dysfunction and CVD. Antioxidant therapy is an attractive avenue for treatment of CVD associated pathologies. Implementation of targeted nano-antioxidant therapies has the potential to overcome hurdles associated with systemic delivery of antioxidants. This review examines the currently available options for nanotherapeutic targeting CVD, and explores successful studies showcasing targeted nano-antioxidant therapy.

Recent Findings:

Active targeting strategies in the context of CVD heavily focus on immunotargeting to inflammatory markers like cell adhesion molecules, or to exposed extracellular matrix components. Targeted antioxidant nanotherapies have found success in pre-clinical studies.


This review underscores the potential of targeted nanocarriers as means of finding success translating antioxidant therapies to the clinic, all with a focus on CVD.


CVD; antioxidant targeted delivery; cardiovascular disease; immunotherapy; nanotherapies; treatments

[Available on 2020-09-01]

Conflict of interest statement

Compliance with Ethics Guidelines Conflict of Interest Ana Cartaya, Sophie Maiocchi, and Edward M. Bahnson declare no conflict of interest.

Supplemental Content

Loading ...
Support Center